Evrenzo tablets 100 mg for renal anemia (roxadustat)

What are Evrenzo tablets 100 mg for renal anemia (roxadustat)?

Renal anemia treatment is crucial for individuals with chronic kidney disease, and Evrenzo tablets offer an effective solution. These tablets contain roxadustat, a HIF prolyl-hydroxylase inhibitor that activates hypoxia-inducible factor (HIF) pathways. By inhibiting HIF prolyl hydroxylase (HIF-PH), Evrenzo prevents HIF degradation, thereby boosting erythropoietin production. This hormone plays a critical role in stimulating red blood cell production, addressing anemia associated with kidney diseases.

Why Choose Evrenzo Tablets for Renal Anemia Treatment?

Evrenzo tablets are designed to target the underlying causes of renal anemia by activating the HIF pathway and stimulating erythropoietin production. This mechanism effectively increases red blood cell production, addressing deficiencies caused by kidney disease. Evrenzo represents an innovative and dependable option for patients requiring treatment for renal anemia.

Scientific Evidence Supporting Evrenzo's Effectiveness

Extensive scientific research supports the efficacy of roxadustat tablets in treating renal anemia. Notably, the study "Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis" demonstrated significant benefits. During an 18-week open-label period, participants experienced an average increase in hemoglobin levels of 1.9±1.2 g/dL. Additionally, mean reductions in hepcidin levels (56.14±63.40 ng) indicated improved iron availability, alongside a notable decrease in total cholesterol levels (40.6 mg/dL). These findings underscore Evrenzo tablets as a potent and reliable choice for treating renal anemia.

Benefits of Evrenzo Tablets

• Improved Hemoglobin Levels: Evrenzo helps maintain and increase hemoglobin levels, ensuring better oxygen transport in the body.
• Enhanced Iron Availability: By lowering hepcidin levels, Evrenzo enhances iron availability for red blood cell production.
• Lower Cholesterol Levels: Evrenzo also contributes to reduced total cholesterol levels, particularly beneficial for individuals with renal anemia.
• Convenient Administration: As an oral medication, Evrenzo provides a convenient and non-invasive treatment option, promoting better adherence to treatment plans.

For individuals seeking an effective treatment for renal anemia, Evrenzo tablets offer a scientifically supported solution that addresses the root causes of the condition. By enhancing red blood cell production and improving iron availability, roxadustat tablets provide a comprehensive approach to managing renal anemia. Trust Evrenzo for a proven, convenient treatment that delivers measurable results.

Active principles: roxadustat

Amount: 30 tablets

Indications: treatment of renal anemia

How to take: 

For patients untreated by erythropoiesis stimulating agent: adults should start taking this medicine with 50 mg of the active ingredient at a time, 3 times a week. Thereafter, your doctor may adjust the dosage according to the condition of the patient. The maximum single dose is 3.0 mg/kg. 

For patients switching from erythropoiesis stimulating agent: adults should start taking this medicine with either 70 mg or 100 mg of the active ingredient at a time, 3 times a week. Thereafter, your doctor may adjust the dosage according to the condition of the patient. The maximum single dose is 3.0 mg/kg.  

This medicine contains 100 mg of the active ingredient in one tablet. 

Take this medicine 3 times a week, at intervals of 2 to 3 days (e.g. on Monday, Wednesday and Friday or on Tuesday, Thursday and Saturday). 

Anemia test (measuring hemoglobin concentration) should be performed before using this medicine. To measure serum concentrations of hemoglobin, blood tests should be periodically performed while using this medicine.

Contraindications and precautions: Do not use for patients with hypertension, malignant tumor, proliferative diabetic retinopathy, macular edema, exudative age-related macular degeneration, retinal vein occlusion or liver dysfunction. Do not use for patients with cerebral infarction, myocardial infarction or pulmonary embolism or a history of those. Do not use for pregnant or breastfeeding women. Female patients should use adequate contraception while taking this medicine and for a certain period of time after the last dose of this medicine. Breastfeeding should be avoided from the start to 28 days after the last dose of this medicine.

Hypertension may occur when using this medicine. Since central hypothyroidism may occur, thyroid function tests should be periodically performed while using this medicine. Patient needs to take iron to get an adequate efficacy. 

If allergic or any other unusual symptoms occur, discontinue use and consult with your doctor.